MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-25-2026
United Therapeutics Corporation Accounts Receivables 2011-2026 | UTHR
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables United Therapeutics Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 350 M | 279 M | 279 M | 220 M | 199 M | 157 M | 151 M | 176 M | 297 M | 214 M | 193 M | 162 M | 126 M | 117 M | 88.7 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 350 M | 88.7 M | 201 M |
Quarterly Accounts Receivables United Therapeutics Corporation
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 379 M | 322 M | 279 M | 342 M | 291 M | 307 M | 279 M | 259 M | 273 M | 134 M | 220 M | 232 M | - | 170 M | 199 M | 213 M | 173 M | 141 M | 157 M | 157 M | 157 M | 157 M | 151 M | 151 M | 151 M | 151 M | 176 M | 176 M | 176 M | 176 M | 297 M | 297 M | 297 M | 297 M | 214 M | 214 M | 214 M | 214 M | 193 M | 193 M | 193 M | 193 M | 162 M | 162 M | 162 M | 162 M | 126 M | 126 M | 126 M | 126 M | 117 M | 117 M | 117 M | 117 M | 88.7 M | 88.7 M | 88.7 M | 88.7 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 379 M | 88.7 M | 192 M |
Accounts Receivables of other stocks in the Biotechnology industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alnylam Pharmaceuticals
ALNY
|
778 M | $ 330.34 | 3.6 % | $ 43.3 B |  USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
830 K | $ 0.44 | -16.64 % | $ 5.04 M |  Israel |
 |
I-Mab
IMAB
|
130 M | - | - | $ 866 M |  China |
 |
Catalyst Pharmaceuticals
CPRX
|
126 M | $ 24.98 | 1.17 % | $ 3.05 B | USA |
 |
Cardiff Oncology
CRDF
|
182 K | $ 1.58 | - | $ 106 M | USA |
 |
Curis
CRIS
|
3.35 M | $ 0.53 | -3.07 % | $ 6.98 M | USA |
 |
Acorda Therapeutics
ACOR
|
17.3 M | - | -24.86 % | $ 820 K | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
592 K | $ 37.7 | 1.26 % | $ 3.55 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
25 M | $ 49.15 | -0.73 % | $ 4.42 B |  Schweiz |
 |
Adverum Biotechnologies
ADVM
|
886 K | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
234 K | - | -9.65 % | $ 45.9 M | USA |
 |
AgeX Therapeutics
AGE
|
57 K | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
200 K | - | 1.93 % | $ 17.4 M | USA |
 |
CytomX Therapeutics
CTMX
|
2.01 M | $ 4.4 | -3.51 % | $ 607 M | USA |
 |
Cue Biopharma
CUE
|
5.55 M | $ 0.18 | -1.61 % | $ 17.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
392 K | - | - | $ 2.17 B | USA |
 |
Aquestive Therapeutics
AQST
|
17.8 M | $ 4.09 | -0.97 % | $ 437 M | USA |
 |
Cyclerion Therapeutics
CYCN
|
556 K | $ 4.15 | -32.52 % | $ 10.4 M | USA |
 |
DBV Technologies S.A.
DBVT
|
2.23 M | $ 20.36 | -3.32 % | $ 2.84 B |  France |
 |
Arcturus Therapeutics Holdings
ARCT
|
5.56 M | $ 8.22 | 2.37 % | $ 225 M | Israel |
 |
Aptinyx
APTX
|
257 K | - | -39.0 % | $ 4.57 M | USA |
 |
Denali Therapeutics
DNLI
|
2.17 M | $ 19.38 | -6.15 % | $ 3.19 B | USA |
 |
Dyadic International
DYAI
|
1.09 M | $ 0.87 | -2.8 % | $ 31.5 M | USA |
 |
Celldex Therapeutics
CLDX
|
2.02 M | $ 31.37 | 1.0 % | $ 2.08 B | USA |